PTPA

Across TCGA pan-cancer cohorts, PTPA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTPA data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTPA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTPA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where PTPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.898	0.582	<.001	74	view →
HNSC	DFS	Median	IV	0.912	0.624	.003	20	view →
PDAC	OS	Tertile	II,III,IV	0.637	0.400	.011	10	view →
LUAD	OS	Tertile	All	1.000	0.929	.010	7	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	4	view →
LSCC	DFS	Quartile	II,III,IV	0.799	1.000	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTPA–CCRCC (DFS)

Open the CCRCC breakdown →